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Abstract 
Background—Phenotypic switching of vascular smooth muscle cells (VSMCs) from a 
contractile to a synthetic state is implicated in diverse vascular pathologies including 
atherogenesis, plaque stabilisation, and neointimal hyperplasia. However, very little is known as 
to the role of long non coding RNA (lncRNA) during this process. Here we investigated a role 
for long non-coding (lnc)RNAs in VSMC biology and pathology. 
Methods and Results—Using RNA-sequencing, we identified >300 lncRNAs whose expression 
was altered in human saphenous vein (HSV) VSMCs following stimulation with IL1Į and 
PDGF. We focused on a novel lncRNA (Ensembl: RP11-94A24.1) which we termed smooth 
muscle induced lncRNA enhances replication (SMILR). Following stimulation, SMILR 
expression was increased in both the nucleus and cytoplasm, and was detected in conditioned 
media. Furthermore, knockdown of SMILR markedly reduced cell proliferation. Mechanistically, 
we noted that expression of genes proximal to SMILR were also altered by IL1Į/PDGF 
treatment, and HAS2 expression was reduced by SMILR knockdown. In human samples, we 
observed increased expression of SMILR in unstable atherosclerotic plaques and detected 
increased levels in plasma from patients with high plasma C-reactive protein. 
Conclusions—These results identify SMILR as a driver of VSMC proliferation and suggest that 
modulation of SMILR may be a novel therapeutic strategy to reduce vascular pathologies.  
 
 
Key words: microRNA; atherosclerosis; non-coding RNA; vascular smooth muscle; 
proliferation; long non-coding RNA 
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Introduction 
Vessel wall remodelling is an integral pathological process central to cardiovascular diseases 
including atherogenesis, plaque rupture and neointimal hyperplasia associated vein graft failure 
and in-stent restenosis 1, 2. Resident vascular smooth muscle cells (VSMC) are typically 
quiescent and contractile in the normal physiological state. However, following pathological or 
iatrogenic vascular injury, the release of cytokines and growth factors from VSMC, aggregated 
platelets and inflammatory cells on the damaged intimal surface, leads to “phenotypic switching" 
of VSMC and the adoption of a more synthetic, pro-proliferative and pro-migratory state 3. In the 
setting of the pathological injury of atherosclerosis, VSMCs not only contribute to the 
atherogenic process itself but can also engender plaque stabilisation through the generation of a 
thick-capped fibroatheroma. For acute iatrogenic vascular injury, over exuberant proliferation of 
VSMC subpopulations promotes neointimal hyperplasia leading to luminal narrowing such as 
seen in vein graft failure or in-stent restenosis 4. Phenotypic switching of VSMCs and release of 
cytokines and growth factors are therefore critical in vascular disease and understanding the 
mechanisms involved is critical to gain insights into pathology and identify new opportunities for 
therapies.  
The highly conserved IL1Į and PDGF pathways play prominent roles in VSMC-
associated pathologies 1, 5. IL1Į is a central mediator in the cytokine cascade and a potent 
activator of vascular cytokine production.  Furthermore, previous studies have demonstrated that 
ligation injury result in reduced neointimal formation in IL-1 receptor knockout mice 6. 
Downstream mediators include the signalling molecules MEKK1, p38 and the transcription 
factor NF-țB that activate mediators of inflammation and cellular migration 7. PDGF is a potent 
mitogen and chemoattractant and expression is increased following vascular injury 8. Conversely 
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a reduction in PDGF expression reduces intimal thickening and cellular content of the neointima 
9. Activation of both IL1Į and PDGF signalling pathways simultaneously can activate common 
downstream targets leading to additive or synergistic effects. This includes activation of NFțB 
leading to the up-regulation of MMP 3 and 9 10: genes critical in the development of 
vasculoproliferative pathologies. 
Over the past decade, there has been substantial interest in determining the complex 
interactions between hierarchical levels of gene regulation. Up to 90% of the human genome is 
transcribed at different developmental stages  and only approximately 2% of RNA molecules are 
translated into protein 11. The functional complexity of organisms therefore appears to be reliant 
upon non-coding RNA molecules. Non-coding RNAs are subdivided into several classes, 
including microRNA (miRNA) and long non-coding RNA (lncRNA). MiRNAs are abundantly 
expressed in vascular tissues and play an important role in vascular pathology. Interestingly, 
recent studies have demonstrated that miRNAs are capable of being released into the blood from 
injured cells. These miRNAs are relatively stable and have been reported as biomarkers for 
several disease states including myocardial infarction 12 and heart failure13, 14. While the role of 
miRNAs is reasonably established in the setting of cardiovascular pathology, relatively little is 
known about the role of lncRNAs. LncRNAs are capable of regulating target DNA, RNA and 
protein at the pre and post-transcriptional level. It is becoming clear that lncRNAs play a pivotal 
role in cellular physiology and pathology via localisation in sub populations of cells and through 
highly controlled temporal expression 15. However, detailed insights into their regulation and 
biological roles are only beginning to emerge. In the vascular setting, SENCR and MALAT1 have 
been implicated in the control of vascular cell migration and endothelial cell sprouting, 
respectively 16, 17. Interestingly, SENCR is implicated in phenotypic switching of VSMCs to a 
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more pro-migratory phenotype as knockdown of this lncRNA downregulates contractile genes 17. 
A greater understanding of lncRNAs in quiescent and proliferative VSMCs may provide 
valuable insight into the specific roles of lncRNAs in response to pathological processes.  
 
Methods 
Human tissue samples 
Surplus human saphenous vein tissue was obtained from patients undergoing CABG. Carotid 
plaques were obtained from patients undergoing endarterectomy following an acute and symp-
tomatic neurovascular event. Human plasma samples were utilised from a previously published 
study: Carotid Ultrasound and Risk of Vascular disease in Europeans and South Asians 
(CURVES) 2. All patients gave their written, informed consent. All procedures had local ethical 
approval (06/S0703/110, 12/WS/0227, 09/S0703/118 and 12/NW/0036). All studies were ap-
proved by East and West Scotland Research Ethics Committees and all experiments were 
conducted according to the principles expressed in the Declaration of Helsinki.  
Tissue and Cell culture 
All cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. Primary 
human saphenous vein derived endothelial cells (HSVECs) were isolated by a modified version 
of the protocol described by Jaffe and colleagues 18 and maintained in large vessel endothelial 
cell culture medium. supplemented with 20% FCS (Life Technologies, Paisley, UK). Primary 
human saphenous vein derived smooth muscle cells (HSVSMC) were isolated from medial 
explants 19 and maintained in Smooth Muscle Cell Growth Medium 2 (PromoCell, Heidelberg, 
Germany) with supplements. Human coronary artery VSMC were purchased from Lonza (Basel, 
Switzerland) and maintained in VSMC media as above.  
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Sample preparation for RNA-seq library construction and analysis 
HSVSMC were plated, quiesced in medium containing 0.2% fetal calf serum for 48 hour before 
the stimulation with 10 ng/ml IL1Į, 20 ng/ml PDGF (R&D Systems) or a combination of both 
for 72 hours. Total RNA was processed through miRNeasy kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions, treated with DNAse 1 (amplification grade; Sigma, St. 
Louis, USA) in order to eliminate genomic DNA contamination and quantified using a 
NanoDrop ND-1000 Spectrophotometer (Nano-Drop Technologies, Wilmington, DE, USA). 
Following bioanalyzer quality control for RNA integrity number (RIN) values >8, RNA-seq was 
performed on ribosomal-depleted RNA using an Illumina Hiseq platform by Beckman Coulter 
Genomics. Paired-end sequencing was carried out with a read depth of 70 million (n=4/group). 
RNA-seq reads were processed and trimmed to ensure quality and remove adapter sequences 
using Flexbar 20 and mapped to the Ensembl annotation of GRCh37.75 using the TopHat2 
version 2.0.9 21. The transcriptome was assembled from the aligned reads and quantified using 
Cufflinks version 2.2.1 22. The differential expression levels between the groups was assessed 
using Cuffdiff version 2.2.1 23. The data set are deposited in the GEO repository, study number 
GSE69637. The biotype of each transcript was annotated according to the Ensembl database. 
Normalisation and statistical analysis of differentially expressed transcripts were carried out 
using edgeR and data filtered to find transcripts that were differentially expressed (p<0.01) 
between 0.2% media and each treatment group. Differentially expressed lncRNAs, between 
control and both IL1Į/PDGF treatment, were explored using more stringent criteria (p<0.01, 
FDR<0.01, LogFC>2) and filtered according to transcript abundance (FPKM>1 in at least one 
group). Data outputs such as pie charts and heatmaps were generated using R. IPA analysis was 
carried out using protein coding genes differentially expressed (FDR<0.01) from Edge R 
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analysis. 
Assessment of RNA secretion from HSVSMC 
RNA extraction on conditioned HSVSMC media was performed using a standard volume (2 
mL). The conditioned media was first centrifuged (10 min; 2000 g; 4°C) to remove all cells and 
debris. After addition of 1.4 mL of QIAzol (Qiagen), 3 μL of c.elegans total RNA at 25 ng/μL 
was added to each sample. Following 5-min incubation at RT, 140 μL of chloroform was added 
and samples centrifuged (15 min; 15000 g; 4°C). The clear upper aqueous phase was used to 
isolate RNA using miRNEasy mini kit (Qiagen) as previously described with alteration of the 
final wash step (75 % ethanol in DEPC water). Different quantities of total RNA were spiked 
and a dose response effect was observed (Suppl. Figure 1A). The quality of the amplicon was 
assessed via analysis of melting curves (Suppl. Figure 1B) and subsequent visualisation on 
agarose gel (Suppl. Figure 1C). This showed a unique amplification product corresponding to 
the cDNA fragment of ama-1. Due to the correlation observed between quantity of spike-in and 
ama-1 expression (Suppl. Figure 1D), we utilised 75 ng in all subsequent extractions. This 
amount allowed reproducibility of our method, with the Ct values of ama-1 being 29.4±0.3 
across 5 separate extractions in non-conditioned media (Suppl. Figure 1E).   
Gene expression quantitative RealTime-PCR (qRT-PCR) 
For gene expression analysis, cDNA for mRNA analysis was obtained from total RNA using the 
Multiscribe Reverse Transcriptase (Life technologies, Paisley, UK). qRT-PCR was performed 
using Power SYBR green (Life Technologies) with custom PCR primers (Eurofins MWG, 
Ebersberg, Germany), the specificity of these primers was confirmed by performing a melting 
curve and running their PCR produce on a gel (Suppl. Table 1 – primer sequences). Ubiquitin C 
(UBC) was selected as housekeeping gene due to its stability across all groups studied. Fold-
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changes were calculated using the 2-ǻǻCt method 23. 
Statistical Analysis 
Statistical analysis was performed according to figure legends. Data in graphs are shown on 
relative expression scales as referenced by 24.  Data are given as both mean ± standard deviation 
(StDev) (shown as bars and whiskers) and also as the individual points in order to clearly 
represent the data. Note that as the relative expression scale is inherently skewed, the bar indicate 
the geometric mean of the relative expression fold change with the StDev whiskers denoting the 
relative expression fold change equivalent to an increase of one StDev above the mean on the log 
transformed scale.  All statistical analysis is performed on the dCt scale (a logarthmic 
transformation of the data shown on the RQ in the plots)24.  No evidence of unequal variances 
across groups was found for any of analyses of the dCt scale data using Levene’s test on minitab 
version 17 prior to statistical analysis. Comparisons between 2 groups were analysed using 2-
tailed unpaired or paired Student’s t test. One-way ANOVA with Tukey’s post hoc or one way 
ANOVA multiple comparison test for pooled samples, via Graph Pad Prism version 5.0, was 
used for comparisons among 3 or more groups. Statistical significance is denoted by a P value of 
less than 0.05. 
Results 
Induction of inflammatory and cell cycle pathways by IL1Į and PDGF 
We sought to identify lncRNAs that are regulated during the induction of proliferative and 
inflammatory pathways in HSVSMC. RNAs were identified using RNA-seq of HSVSMC treated 
for 72 h (Figure 1A). Activation of the IL1Į and PDGF signalling pathways was confirmed by 
presence of the inflammatory microRNA miR-146a (Figure 1B) and induction of VSMC 
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proliferation (Figure 1C). The RNA-sequencing obtained an average of 70 million reads per 
sample; with 93.5% aligning to the GRCh37 genome reference files. The majority of reads, 
under all conditions, corresponded to mRNA (49.6±0.48 %; Figure 1D and Suppl. Figure 2A). 
To identify the biological function, networks, and canonical pathways that were affected by 
VSMC stimulation, we performed Ingenuity Pathway Analysis (IPA) after RNA-seq analysis. 
IPA confirmed the mRNAs with altered expression following IL1Į treatment were significantly 
enriched in pathways related to cellular movement and inflammatory disease (Suppl. Table 2), 
while PDGF stimulation led to the marked enrichment in cell cycle pathways (Suppl. Table 3). 
Interestingly, co-stimulation led to enrichment in cell cycle and cardiovascular development 
pathways (Suppl. Table 4). Further analysis of differentially expressed mRNAs with a stringent 
cut off of FDR<0.01 identified 518 protein coding genes altered following IL1Į treatment and 
540 following PDGF treatment. Notably, dual stimulation altered 1133 known protein-coding 
genes with 480 uniquely associated with dual stimulation and not affected by IL1Į or PDGF 
treatment alone (Figure 1E and Suppl. Figure 2B).  
Identification of differentially expressed LncRNAs in HSVSMC treated with IL1Į and PDGF 
We next assessed whether lncRNAs were dynamically regulated by growth factor and cytokine 
stimulation. Approximately 33% of reads in each condition aligned to known or predicted 
lncRNAs (Suppl. Figure 3A). Differential expression analysis confirmed substantial differences 
in lncRNA expression between control and stimulated cells. Using the stringent criteria FDR 
0.01 and log2 fold change (FC) 2, to declare significance and fragments per kilobase of exon 
per million fragments mapped (FPKM) >1, to confirm quantifiable expression we identified 224, 
215 and 369 differentially expressed lncRNAs following IL1Į, PDGF or dual stimulation 
respectively (Suppl. Figure 3A). Since lncRNAs can typically contain multiple splice variants, 
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the numbers quoted refer to a single consensus gene model and therefore do not reflect the 
multiple transcripts of each lncRNA. To determine if specific biotypes of lncRNA were enriched 
following HSVSMC stimulation, those differentially expressed were further subdivided 
according to biotype in the Ensembl database. These are based upon their relative orientation to 
protein coding genes; intervening lncRNA (lincRNA), antisense, overlapping and processed 
transcripts. Utilising control and dual stimulation as an example, the distribution of different 
lncRNA biotypes was: intervening (45.5%), antisense (45.3%), overlapping (1.4%) and 
processed transcripts (7.9%) (Suppl. Figure 3B). Focusing on lincRNA, the candidates (control 
vs IL1Į and PDGF, FDR<0.01, LogFC<2, FPKM>1) were ranked according to their FPKM and 
level of up/down-regulation (Figure 2A, suppl Figure 4 for heat map of all conditions). A 
subset of the most differentially expressed transcripts was identified and validated by qRT–PCR 
(RP11-91k9.1, RP11-94a24.1, RP11-709B3.2, RP11-760H22.2 and AC018647.3; Figure 2B, 
chromosomal locations in Suppl. Table. 1). This was consistent with the RNA-seq results, 
showing RP11-94a24.1 and RP11-91k9.1upregulated 20.2±30and 45±26.4 fold, respectively 
following co-stimulation and lncRNAs RP11-709B3.2, RP11-760H22.2 and AC018647.3 being 
down regulated 16, 28 and 1209 fold, respectively (Figure 3A) (RQ = 0.06±0.04, 0.035±0.01 
and 0.0008±0.001 respectively). The dissociation curves and gel products of each primer set are 
shown in Supplemental Figure 5. 
Vascular enriched expression of RP11-94a24.1 
The expression of each lncRNA was quantified in a range of 10 normal human tissues including 
specimens derived from brain, gastrointestinal, reproductive, and endocrine systems. In general, 
lncRNAs were expressed at relatively low levels across the tissue panel. However, we observed 
that RP11-91k9.1 was expressed highest in the heart, while RP11-91K9.1 and AC018647.3 
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showed preferential expression within the liver and brain respectively. RP11-709B3.2 and RP11-
760H22.2 displayed highest expression in spleen and thyroid respectively (Suppl. Figure 6A). 
We next examined the expression of each lncRNA in primary HSVEC, HSVSMC and human 
coronary artery SMC (HCASMC). All lncRNAs had higher expression in VSMCs of either 
venous or arterial lineage compared to endothelial cells, suggesting VSMC enrichment (Suppl. 
Figure 6B). We also assessed whether the expression of these lncRNAs could be modulated by 
IL1Į and PDGF in HSVEC as had been found in the HSVSMCs. Notably, subsequent down 
regulation of RP11-709B3.2, RP11-760H22.2 and AC018647.3 was not observed in HSVECs as 
was the case in HSVSMC (data not shown). Stimulation of HSVECs produced a significant 
3.8±0.7 and 8.7±2.1 fold up regulation of RP11-91K9.1 following IL1Į and IL1Į/PDGF 
treatment respectively (Figure 3B). However, stimulation had no effect upon RP11-94a24.1 
expression (Figure 3B), indicating selective regulation in HSVSMC. Due to the expression of 
RP11-94a24.1 in HSVSMC and its cell specific induction in response to pathological mediators 
of vascular injury, we focused further studies on RP11-94a24.1. We termed this lncRNA, smooth 
muscle induced lncRNA enhances replication (SMILR). SMILR expression was assessed through 
the utilisation of 3 independent primer sets targeting differential exons of the LncRNA. qRT-
PCR revealed similar Ct and fold changes amongst the 3 sets, further confirming our previous 
data (Suppl. Figure 7). The longest open reading frame within SMILR is 57 amino acids. 
Analysis of this open reading frame using the Coding Potential Calculator 
(http://cpc.cbi.pku.edu.cn) did not reveal any similarity to known protein coding sequences 
suggesting that this RNA has no protein coding potential (data not shown).  
IL1Į/PDGF treatment induces the expression of SMILR in a time dependent manner 
To investigate the longitudinal regulation of SMILR, we stimulated HSVSMC with PDGF, IL1Į 
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or a combination of both (1.5 h, 4 h, 24 h, 48 h and 72 h). We found significant up regulation of 
SMILR in response to PDGF as early as 4 h post stimulation. By 24 h SMILR expression was 
increased by treatment with PDGF or IL1Į as well as both together (Suppl. Figure 8). The 
combination of PDGF and IL1Į induced a synergistic increase in SMILR expression at 72 h.   
Cellular localisation of SMILR in HSVSM cells 
Rapid amplification of cDNA ends 25, was utilised to design specific RNA FISH probes. RNA-
FISH highlighted a SMILR isoform, consisting of an additional 6bp at the 5’ end and 316bp at 
the 3’ end (Suppl. Figure 9A and B). RACE data is supported by the raw RNA-seq files (Suppl. 
Figure 10 A-C). 
We performed RNA-FISH to provide visuospatial information as to the location of 
SMILR within HSVMSC. Negative control samples showed no fluorescent signal while 
SNORD3 fluorescent activity confirmed the nuclear permeabilisation of cells (Figure 4A). In the 
absence of growth factor and cytokine stimulation, HSVSMC typically exhibited between 0 and 
3 positive fluorescent signals corresponding to SMILR localisation (Figure 4A). IL1Į/PDGF 
treatment induced a marked increase in fluorescent signal within the nucleus and cytoplasm of 
HSVSMC. Further specificity of the FISH probes was confirmed through the utilisation of cells 
treated with either lentivirus containing SMILR or siRNA targeting SMILR. In each case an 
increase and decrease in SMILR transcripts was observed (Figure 4A). Quantification of FISH 
samples is provided in Figure 4B. In the absence of stimulation 2±3.6 SMILR molecules were 
observed. Following stimulation, 25±5 individual SMILR molecules were observed within the 
nucleus and cytoplasm (Figure 4B). 
Identifying upstream mediators of SMILR expression in HSVSMC 
It is well established that IL1Į and PDGF work through distinct pathways leading to vascular 
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cell activation. To assess the functional consequences of inhibition of these pathways on SMILR 
expression, selective pharmacological inhibitors AZD6244 (MEKK1) and SB 203580 (p38) were 
utilised (Figure 5A). Following 60 min pre-treatment with inhibitors, VSMC were stimulated 
with IL1Į/PDGF and the expression of SMILR was determined at 24 h. Pre-treatment with 
AZD6244 (5, 10 or 15 μM) prevented the induction of SMILR in response to PDGF and IL1Į 
(Figure 5B), while inhibition of p38 with SB203580 induced a dose-dependent reduction in 
SMILR expression in response to PDGF and IL1Į (Figure 5C). 
IL1Į/PDGF treatment induces the release of SMILR into conditioned media 
MicroRNAs have been reported to be secreted from cells as a means of cell to cell 
communication 26. To investigate whether HSVSMCs release SMILR as an indication of 
expression, we modified a method commonly utilised to evaluate miRNA expression 27. As no 
endogenous control was stably expressed across all conditions in this study, an exogenous 
control was added in order to monitor extraction efficiency and to normalise data. Consequently, 
total RNA from C.elegans was used as a spike-in and ama-1 encoding polymerase II was chosen 
as a control for its high constitutive expression (see methods). Interestingly, SMILR was detected 
at low levels in media from quiesced VSMCs and those stimulated by either PDGF or IL1Į, 
while conditioned media obtained from VSMC stimulated by combination contained 
significantly higher levels of SMILR (4.8±4.5 fold) (Figure 5D), consistent with the increased 
intracellular expression of SMILR following co-stimulation of VSMC. Thus, treatment with 
PDGF and IL1Į increased intracellular and released levels of SMILR.  
Additionally we sought to identify if SMILR was encapsulated within exosomes or 
microvesicles (MV).  We utilised both ultracentrifugation, to remove cell debris, and an exosome 
isolation kit. Supplemental Figure 11A and B confirms the presence of microvesicles and 
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exosomes using Nanosight technology and the expression of the previously described miR-143 
within the exosomes/MV 28. Our data highlights the expression of SMILR restricted to exosome 
free media (Suppl. Figure 11C) and inability to detect SMILR expression in the exosomes/MV 
compartment using both techniques of isolation. This observation has been confirmed by agarose 
gel electrophoresis (Suppl. Figure 11D).  Primer melting curves are also shown in 
Supplemental Figure 11E. Our data confirm that SMILR is secreted into the media and located 
in a non-exosome/MV fraction. This could possibly be through interaction with specific 
membrane channels but requires additional experimentation.  
Additionally, we examined the release of SMILR following lentiviral overexpression in 
IL1 and PDGF treated cells. Lentiviral overexpression resulted in a 10-fold increase in SMILR 
RNA intracellularly. However, only a marginal (not significant) increase was observed within 
conditioned media analysed from infected cells (Suppl. Figure 11F). When this media was 
transferred onto additional quiesced cells, no change in proliferation was detected (Suppl. 
Figure 11G). This may suggest that the release of SMILR is under stringent control mechanism 
and simply increasing SMILR expression via lentiviral approach is not sufficient to induce the 
additional release of this lncRNA from the cells. In addition, these cells were stimulated with IL1 
and PDGF, which strongly enhances SMILR expression in VSMC. The secretory machinery may 
have been saturated with the high levels of LncRNA within the cytoplasm. This has previously 
been demonstrated with microRNA where high levels of miR, via overexpression with 
microRNA mimics, saturated the exportin-5 pathway of endogenous miRNAs with fatal 
consequences29, 30.  
Effect of dicer substrate siRNA mediated knockdown of SMILR on HSVSMC proliferation 
We investigated the function of SMILR using dicer substrate siRNA (dsiRNA)-mediated 
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knockdown and EdU incorporation. Forty-eight hours post stimulation, IL1 and PDGF treatment 
induced a 34±15% increase in VSMC proliferation compared to control (Suppl. Figure 12). 
DsiRNA SMILR caused 75±24% decrease in SMILR expression when compared to dsiControl 
(Figure 5E). Following SMILR knock down with dsiRNA, VSMC proliferation was reduced by 
56±15% (Figure 5F). Results were confirmed through the use of a second dsiRNA targeting an 
alternative region of SMILR (Suppl. Figure 13A and B). No effect on the interferon pathway 
was observed upon assessment of the response genes OAS1 and IRF7, which have previously 
been linked to disRNA off target effects 31 (Suppl. Figure 13C and D).  
Additionally the effect of SMILR overexpression on SMC proliferation was investigated. 
SMC were infected with SMILR lentivirus or empty control for 24 hours prior to stimulation. 
Infection at a multiplicity of infection of 25 and 50 produced a 5.5 ± 3.5 and 11.4 ± 4.7 fold 
increase in SMILR expression compared to the empty control, with no apparent toxicity effects 
(Figure 5G). Overexpression produced a dose dependent increase of 1.3 ± 0.3 fold and 1.66 ± 
0.5 fold in SMC proliferation respectively (Figure 5H), confirming the knock down data.  
SMILR expression correlates with other proximal genes 
The expression of lincRNAs can correlate with the expression of adjacent genes and other RNAs 
within the genomic locale 32. We therefore assessed the expression of genes and non-coding 
RNAs within 5 million base pairs of SMILR, from COL14A1 on the forward strand to FERIL6-
AS1 on the reverse strand (Figure 6A), using the RNA-seq data set (Figure 6B). Up-regulation 
of SMILR was not associated with a widespread increase in transcriptional activity within the 
region (Figure 6B). However, similar changes in expression in response to VSMC stimulation 
were observed in two proximal transcripts (HAS2 and HAS2-AS1). SMILR is located ~750 kbp 
downstream of HAS2 on the same (reverse) strand and ~350 kbp from ZHX2 and ~ 750 kbp from 
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HAS2-AS1 on the opposite strand of chromosome 8 (Figure 6C). The upregulation of HAS2 was 
accompanied by an increase in HAS1 but not HAS3 following dual stimulation (Figure 6 D-F). 
Interestingly, IL1 and PDGF in combination had no effect on HAS3 expression as IL1 and 
PDGF have opposing effects on HAS3 expression (Full graph with single stimulation Suppl. 
Figure 13 E and F). In addition to SMILR, up-regulation of HAS2-AS1 was evident following 
IL1Į and PDGF treatment, but not ZHX1 in the RNA-seq data (Data not shown).  This 
observation was validated by qRT-PCR (Figure 6 G,H and I). 
It has been previously shown that lncRNA can modulate the expression of nearby protein 
coding genes. Thus, the expression of proximal genes HAS2, ZHX2 and HAS2-AS1 were 
determined following SMILR knockdown. RNAi-mediated knockdown of SMILR significantly 
altered levels of HAS2 mRNA. However, no change in the HAS2-AS1 lncRNA or the ZHX2 gene 
was observed via qRT-PCR (Figure 6 J-L). Results were confirmed using a second siRNA 
targeting SMILR (Suppl. Figure 13 G - I). Additionally, no effect on HAS1 or HAS3 expression 
was observed while utilising SMILR siRNA indicating that the effect of SMILR knockdown is 
specific to HAS2 and not all isoforms of HAS (Figure 6 M and N). 
Additionally, knockdown of HAS2-AS1 greatly reduced HAS2 expression with no effect 
on SMILR expression (Suppl. Figure 14 A and 14B). However, the reverse experiment utilising 
HAS2 knockdown, did not affect the expression of HAS2-AS1 nor SMILR (Suppl. Figure 14C). 
Finally, lentiviral mediated overexpression did not affect HAS1, 2,3 or HAS2-AS1 expression 
(Suppl. Figure 14 D-G). 
SMILR expression is dysregulated in unstable human carotid plaques 
To investigate the importance of SMILR in human vascular pathologies, we assessed levels of 
SMILR in unstable atherosclerotic plaques. We used two established inflammatory ([18F]-
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fluorodeoxyglucose (FDG) and calcification ([18F]-fluoride) PET radiotracers to define 
prospectively portions of high-risk plaque 33 34 35 for RNA extraction. Plaque and relatively 
‘healthy’ adjacent sections of vessel were assessed from within individual patients (Suppl. Table 
5 for patient characteristics). This is of key importance as it permits the assessment of non-
coding RNA expression from within each micro environment (plaque vs. non plaque) from 
within the one vessel. Compared to quiescent adjacent tissue, portions of high-risk plaque 
showed higher uptake of both [18F]-FDG (maximum tissue-to-background ratio (TBRmax) 
1.81±0.21 versus 1.31±1.6) and [18F]-fluoride (TBRmax 2.32±0.52 versus 1.31±0.43) indicating 
that plaques subjected to RNA analysis had enhanced rates of inflammation (Figure 7A-G for 
image examples and Figure 7 H-K for graphs of tracer uptake). Since non-coding RNAs have 
not been assessed in a similar sample set before, we first confirmed whether expression of a 
panel of miRNAs associated with atherosclerosis processes were dysregulated 36. As expected, 
inflammation-associated miRNAs 146a-and 146b were significantly upregulated in unstable 
plaques compared to adjacent quiescent tissue, while miR-29 and miR-204, which are inversely 
associated with osteoblastogenesis and arterial calcification, were down regulated in mineralised 
regions of the atherosclerotic plaque 37, 38.  In addition we also found a downregulation of the 
miR-143/145 cluster, which is associated with SMC differentiation and aortic aneurysm 
formation 39, an event which has previously been linked to osteogenic differentiation of SMC 
(Figure 7L). Thus expression of small non-coding RNAs (miRs) was associated with PET/CT 
defined high-risk plaques. Therefore, we utilised the same cohort of samples to assess SMILR, 
HAS2 and HAS2-AS1 levels. A 3.9±2.3 fold increase in SMILR expression was observed in high-
risk plaques compared to adjacent stable regions of the carotid artery (Figure 7M). Intriguingly, 
we also observed an increased in HAS2 (Figure 7N) but not HAS2-AS1 (Figure 7O). 
 at UNIV OF EDINBURGH on May 9, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.115.021019 
18 
SMILR is detectable in human plasma and correlates with inflammatory CRR 
Due to the release of SMILR into conditioned media from VSMC following stimulation with 
inflammatory mediators, we evaluated whether SMILR was detectable in stored samples from a 
cohort of men with varying metabolic dysfunction. These samples were ranked in order of the 
serologic parameter CRP levels into 3 groups: CRP <2, CRP 2-5 and CRP >5 mg/L representing 
broad tertiles of CRP. SMILR showed no difference in patients with CRP levels below 2 mg 
versus 2-5 mg/L. However, a 3.3±5.7 fold increase in SMILR was observed when CRP 
concentrations were greater than 5 mg/L (Figure 8A). Furthermore, a significant positive 
correlation was seen between SMILR and CRP (R2=0.33, P<0.0001) (Figure 8B). There was no 
correlation between SMILR and additional risk factors including age (P=0.66), blood pressure 
(P=0.12), BMI (P=0.14) or social deprivation status (P=0.11) (Suppl. Table 6).  Melting curves 
and gel products of SMILR primers in plasma are shown in Supplemental Figure 15. Further 
information regarding the statistical analysis of SMILR CRP correlation can be found in 
Supplemental Figure 16.  
Discussion 
We have shown that stimulation of HSVSMCs with PDGF and IL1Į increases expression of 
SMILR. This novel lincRNA increases cell proliferation which may be linked to its ability to 
regulate the proximal gene HAS2. In a clinical setting, we found increased expression of SMILR 
in unstable atherosclerotic plaques suggesting an association with fundamentally important 
vascular pathologies linked to inflammation and VSMC proliferation. We also discovered that 
SMILR can be released from cells and is detectable in plasma from patients with enhanced 
inflammation and thus susceptibility to atherosclerosis. These findings support the growing body 
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of evidence that non-coding RNAs can act as mediators to modulate disease pathways.  
Recent advances in RNA-sequencing have demonstrated that previously thought 
"genome deserts" are in fact pervasively transcribed and are populated by lncRNAs. Utilising 
paired end-sequencing allowed accurate alignment of reads to the human genome (GRCh37), the 
93% alignment rate met quality standards for the RNA-seq technique 40 and ensured that our 
RNA-seq provided a high quality profile of the HSVSMC transcriptome during quiescent and 
stimulated conditions. Notably, compared to control cells, protein-coding genes accounted for 3-
4 fold greater abundance than lncRNAs. Our RNA-seq depth of 70 million reads was sufficient 
to identify lncRNAs within VSMC, however, it should be noted that greater read depths and use 
of refined capture-seq technique would be beneficial in order to offer greater annotation of 
specific areas within the genome. 
Analysis of the RNA-seq data pinpointed SMILR as an IL1Į/PDGF responsive lincRNA 
located on chromosome 8, 750 kbp from the closest protein-coding gene, on the same strand. 
This gene, HAS2, encodes an enzyme which synthesises hyaluronic acid (HA), a critical 
component of the extracellular matrix that accumulates in human restenotic and atherosclerotic 
lesions 41, 42. Our results show knockdown of SMILR reduces HAS2 expression and VSMC 
proliferation. This mechanism of action is supported by a number of studies demonstrating HA 
can enhance VSMC proliferation and migration 43. Recent studies using transgenic mice with 
VSMC specific over-expression of HA have found increased susceptibility to atherosclerosis 44 
and enhanced neointima formation in response to cuff injury 45. The ability of SMILR to 
specifically target HAS2 with no effect on HAS1 or HAS3 allows a means of specifically 
altering HAS2 expression, the main HAS isoform expressed and functioning in SMC 
pathology46. 
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LncRNAs can regulate other RNAs via a number of mechanisms 47, including changes in 
chromatin signatures within their locus. For example, the HOTAIR lncRNA is capable of 
repressing transcription in trans across 40 kbp of the HOXD locus 48. Thus SMILR may act as an 
enhancer or scaffold via interaction with the promoter region, and potentially other transcription 
factors of HAS2, to regulate expression following inflammatory cytokine stimulation. However, 
further detailed co-immunoprecipitation or site directed mutagenesis studies would be required 
to demonstrate whether SMILR participates in transcription factor complexes with NF-țȕ or 
other transcription factors. Previous work has found HAS2 is regulated by an additional lncRNA, 
HAS2-AS1 49. Interestingly, our RNA-seq data show HAS2-AS1 expression was also upregulated 
by PDGF treatment alone and in combination with IL1Į. However, knockdown of SMILR did 
not alter HAS2-AS1 expression. LncRNA HAS2-AS1 modulates chromatin structures around the 
gene in order to allow more efficient binding of the RNA polymerase 2, and enhance HAS2 gene 
expression49. This suggests both SMILR and HAS2-AS1 can regulate HAS2 by independent 
mechanisms. Interestingly, knockdown of HAS2 did not affect either SMILR nor HAS2-AS1 
expression indicating that the expression of these lncRNA are not directly linked to HAS2 
expression.  
The composition of ECM assists in the determination of the stability of the 
atherosclerotic plaques, the phenotype of cells within it and the volume of neointima. During the 
progression of atherosclerosis, VSMC are exposed to a plethora of signalling molecules, 
including inflammatory cytokines. Using the clinical gold-standard methods of 18F-FDG and 
18F-fluoride PET/CT imaging to identify inflamed, necrotic and mineralising atherosclerotic 
plaque 33 34, our results indicate miRs 29, 143, 145, 146 and 204 are differentially expressed in 
unstable regions of atherosclerotic plaques. These miRs have previously been linked to VSMC 
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differentiation, inflammatory cell signalling 50 and VSMC calcification 51. The strong association 
and co-localisation of SMILR with this classical miRNA profile and focal 18F-FDG and 18F-
fluoride uptake within atherosclerotic plaque suggests that SMILR may play a role in 
atherosclerosis through inflammatory and proliferative pathways. In keeping with our results 
showing HAS2 regulation by SMILR, HA content has been shown to reflect the progression of 
atherosclerotic disease and promotes vessel wall thickening52. Indeed, HA has been implicated in 
the recruitment of inflammatory cells, known to play a prominent role in the initiation and 
progression of atherosclerotic lesion to an unstable plaque phenotype.  
Our results demonstrate SMILR is up-regulated by a combination of PDGF and IL1Į in 
VSMCs but not ECs, suggesting modulation of SMILR could specifically alter VSMC 
proliferation without detrimental effects on vessel re-endothelialisation. If this is the case, it 
would provide a suitable candidate to improve current anti-proliferative therapies since current 
pharmacological agents target cell proliferation in a non-cell specific manner, events which can 
lead to late stent thrombosis 53.  
The ability to identify confidently a plaque, or patient, at particular risk of a major 
adverse cardiovascular event (i.e plaque rupture) remains an important goal of Cardiovasc Res. 
Long RNA, both mRNA and non-coding RNA, have been previously shown to be stable in vivo 
for up to 3 weeks 54. As such the search for prognostic biomarkers has greatly increased in recent 
years. SMILR was expressed in both the nucleus and cytoplasm of cells following stimulation 
and was released into the media. It will be important to determine whether the cytoplasmic 
copies induce functional effects, such as regulation of gene expression through post-translational 
mechanisms or if they are simply being processed for release. Dual transcriptional functions of 
lncRNAs have been shown previously55, but to date no reports of a single lncRNA affecting both 
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transcription and translation have been published. The release of SMILR could affect function in 
neighbouring cells, particularly in a vascular injury setting where phenotypic switching of 
VSMCs occurs in distinct areas of the vessel wall. In support of this theory, it has been shown 
that miR 143/145 can be transferred from VSMC into EC56. This transfer produced physiological 
effects within EC including modulation of angiogenesis. We also found that SMILR could be 
detected in the plasma of patients with higher CRP levels indicative of chronic low grade 
inflammation. In light of our studies, we propose this release could be due to the increased levels 
of SMILR in the diseased vasculature, although delineating whether plasma SMILR is simply a 
by-product of increased intracellular levels or is functionally active in disease pathology is 
difficult to definitely demonstrate. However, circulating levels of miR 143 and 145 are 
associated with in-stent restenosis and as such have been proposed as biomarkers57. The 
correlation of SMILR and high CRP further supports its expression in low grade chronic 
inflammatory settings as well as proliferative settings. Further large clinical cohorts will be 
required to ascertain if SMILR has prognostic potential in inflammatory vascular disease, and if 
so, whether it provides enhanced prognostic value over current biomarkers.  
Vessel re-narrowing after surgical intervention and atherosclerosis remain significant 
clinical problems and HA/HAS2/SMILR have emerged as key components of these pathological 
processes. Administration of an siRNA targeting SMILR could be used to prevent re-narrowing 
after surgical intervention for acute coronary syndrome. Using siRNAs has been proven to be 
effective in phase I clinical trials. Davis et al. recently showed a dose-dependent increase of 
siRNA delivered via nanoparticles and observed a reduction in the specific mRNA target58. 
However, we must remain cautious, since early clinical trials in the setting of vein graft failure 
suggested that antisense oligonucleotides directed again E2F (edifoligide) held promising for the 
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treatment of vein graft failure and atherosclerosis, but the subsequent phase-three PREVENT IV 
study yielded largely disappointing results 59.  However, these studies do demonstrate that the 
surgical setting of coronary artery bypass grafting provides the ideal clinical setting to evaluate 
the clinical efficacy of these targets by gene therapy, given that the vein can be transduced ex 
vivo at the time of surgery Administration of siRNA directly to the vessel would obviate the need 
to administer siRNA systemically and thus reduce the possibility of off target effects.  
Unfortunately, there are no clear homologues of SMILR in the mouse. It would, however, be 
important to determine if other pre-clinical models of human vascular disease contain SMILR 
homologues, once this information becomes available. 
Taken together, these observations broaden our awareness of the complex interplay 
between lncRNA and protein coding genes. The emergence of lncRNAs as regulators of gene 
expression will undoubtedly alter our understanding of the complex regulation network of 
pathological VSMC proliferation in vascular disease and may provide a means to specifically 
target VSMC or identify patients at risk of major adverse vascular outcomes.  
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Clinical Perspective 
Long noncoding RNAs (lncRNAs) are a relatively new class of discovered RNA molecules that 
possess important regulatory functions. The rapidly expanding catalogue of lncRNAs holds 
promise that in the near future lncRNAs might become relevant to vascular disease clinically, as 
possible biomarkers of cardiovascular events and for targeted treatment of disease. Our work 
indicates that dysregulation of key lncRNAs may have profound implications in regulating 
vascular smooth muscle cell function. In addition, we detected the release of this lncRNA in 
plasma samples and correlated with inflammatory CReactive Protein (CRP) levels, highlighting 
new methods and possibilities for improved detection. The emergence of lncRNAs as regulators 
of gene expression and vascular function will undoubtedly alter our understanding of the 
complex regulation network of cell function underpinning clinical vascular disease. 
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Figure Legends: 
Figure 1. RNA sequencing shows IL1Į and PDGF induction of inflammatory and cell cycle 
pathways. (A): Study design for determination of the transcriptome in quiescent and stimulated 
HSVSMC. HSVSMC were treated for 72 h, RNA quality assessed and subjected to RNA-seq 
following the Tuxedo pipeline for analysis. (B): Known inflammatory microRNA, miR146a, is 
upregulated by IL1Į (n=4). **P<0.01 vs. 0.2% condition. Multiple comparison one-way 
ANOVA. (C): BrdU incorporation as an indirect marker of proliferation was assessed in all pa-
tients. (n=3). **P<0.01 vs. 0.2% condition. (D): Biotype distribution of all transcripts identified 
by RNA-seq analysis generated from HSVSM cells treated with IL1Į and PDGF, cutoff at 
FPKM>0.1 (E): Venn diagram indicating overlap of protein coding genes with altered expression  
(analysed using EdgeR, FDR<0.01) across each treatment.  
 
Figure 2. Identification of differentially expressed LncRNAs in HSVSMC treated with IL1Į and 
PDGF. (A): Heatmaps showing order of differentially expressed transcripts within the 4 patient 
samples before and after IL1Į/PDGF treatment. LncRNA selected for validation marked by * 
(B): Heatmap representing the fold change of the 5 lncRNAs selected for validation. Heatmaps 
represent data from RNA-seq pipeline. 
 
Figure 3. Treatment with IL1Į and PDGF significantly altered LncRNA expression and showed 
distinct expression within vascular cell types. (A): Graphs indicate fold change of lncRNA from 
RNA-seq data and subsequent validation by qRT-PCR (n=4). * P<0.05, ** P<0.01, *** P<0.001 
vs 0.2% condition.  (B): Basal and stimulated expression of lncRNAs 2 and 7 within HSVEC and 
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HSVSMC (n=4 for SMC and n=3 for EC, * P<0.05, ** P<0.01, *** P<0.001 vs 0.2% in each 
specific cell type).  
 
Figure 4. Localisation of SMILER. (A): RNA FISH analysis of SMILR, cytoplasmic UBC mRNA 
and nuclear SNORD3 RNA in HSVSMC, Magnification x630 for all panels. UBC and SNORD3 
used for confirmation of cellular compartments (B): Quantification of LncRNA molecules per 
cell in indicated conditions. Greater than 5 images were selected at random from each condition 
and at least 4 cells counted in each image.  
 
Figure 5. Functional regulation of SMILR. (A): Schematic diagram showing specific sites of in-
hibition. HSVSMC were pre-treated for 60minutes with the indicated concentration of the inhibi-
tors. Following exposure to vehicle or 10ng/ml IL1 or 20nM PDGF for 24 h expression of 
SMILR was determined by qRT-PCR. (B): SMILR expression following MEKK1 inhibition. 
***P<0.01 vs 0.2% media, ### P<0.001 vs IL1/PDGF treatment. Repeated measures ANOVA. 
n=3. (C): SMILR expression following p38 inhibition. Repeated measures ANOVA. ***P<0.01 
vs 0.2% media, ### P<0.001 vs IL1/PDGF treatment alone n=3. (D): SMILR expression in con-
ditioned media from HSVSMC cultured in 0.2%, IL1 or PDGF conditions. Unpaired t test * 
P<0.05 vs. 0.2% (n=4). (E): Confirmation of the effect of siRNA targeting SMILR in HSVSMC 
using qRT-PCR (n=3). One way ANOVA ***P <0.001 vs. 0.2% control. ### P<0.001 vs IL1 + 
PDGF treatment. (F): IL1/PDGF induced proliferation classed as 100% for analysis across pa-
tient samples, knockdown of SMILR inhibits EdU incorporation in HSVSMC (n=3) One way 
ANOVA vs Si Control. ## P<0.01 (G): qRT-PCR analysis of SMILR expression following infec-
tion with either an empty lentivirus (LV-E) or lentivirus containing SMILR sequence (LV-S) at 
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an MOI of 25 (n=3) and MOI 50 (n=3) ***P<0.001 vs. relevant empty control assessed via mul-
tiple comparison ANOVA.  
 
Figure 6. SMILR regulates proximal gene HAS2 in chromosome 8. (A): Schematic view of the 
8q24.1 region showing lncRNAs and protein coding genes over the 5,000,000 bp region from 
Ensemble. (B): Regulation of protein coding and non-coding genes within the selected region 
following IL1Į and PDGF treatment, heatmap depicts expression of genes found with RNA-seq 
in 4 patient samples. (C): Dotted line marks region containing SMILR lincRNA and closest pro-
tein coding genes HAS2 and ZHX2. (D): Expression of proximal gene HAS2 - modulated in the 
same manner as SMILR with IL1Į and PDGF treatment (n=3). Un-paired t-test ***P<0.001 vs. 
0.2% (E-F): Additional HAS isoforms are differentially modulated by IL1 and PDGF (n=3). Un-
paired t test ***P<0.001 vs. 0.2% (G-I): Validation of RNA seq data for lncRNAs SMILR and 
HAS2-AS1 by qRT-PCR (n=3). *<0.05 and ** P<0.01 vs 0.2%,Un-paired t test. (J): Inhibition of 
SMILR expression via dsiRNA treatment significantly inhibits HAS2 expression determined by 
qRT-PCR **P<0.01 vs. Si Control. Un-paired t test (n=3). (K-N): SMILR inhibition had no ef-
fect on proximal genes ZHX2 or HAS2-AS1 nor additional HAS isoforms, HAS1 or HAS3 
(n=3). Un-paired t test.  
 
Figure 7. Uptake [18F]-Fluoride and [18F]-FDG within plaque and normal artery and changes in 
non-coding RNA expression within carotid plaques. Axial images demonstrating unilateral (A, 
B) or bilateral [18F]-Fluoride carotid uptake (D, E). Image C is a multi-planar reformat of B. Ax-
ial images demonstrating [18F]-FDG carotid uptake (F, G). H shows the Siemens Biograph 
Clinical PET/CT system used for imaging. White arrows indicate carotid radio-ligand uptake. 
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(H-K): Uptake of tracer (L): MicroRNA profile of atherosclerotic plaque and paired healthy ca-
rotid controls (n=6) assessed by qRT-PCR (paired students t test). Expression of SMILR (M), 
HAS2 (N) and HAS2-AS1(O) within atherosclerotic plaque (n=5). analysed via qRT-PCR analy-
sis, *** P<0.001, ** P<0.01 and * P<0.05 assessed by paired students t test.  
Figure 8. SMILR is detectable within plasma samples and correlates with patient CRP levels. 
(A): SMILR expression is increased in patients with higher CRP levels (n=13 CRP<2, n=13 
CRP2-5 and n=15 CRP>5, *P<0.05, **P<0.01 via One-way ANOVA). (B): Correlation between 
SMILR expression and CRP levels (linear regression P<0.0001). 
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
 
Tissue and Cell culture 
Endothelial media supplemented 20% FCS (Life Technologies, Paisley, UK). HSVSMC 
media supplemented with 15% foetal bovine serum (FBS) (PAA laboratories, Yeovil, UK), 2 
mM L-Glutamine (Invitrogen, Paisley, UK) 50 μg/ml penicillin (Invitrogen) and 50 μg/mL 
streptomycin (Invitrogen). All cells were used between passages 3-5. 
 
 
HSVSMC BrdU and EdU Incorporation assay 
HSVSMC proliferation was quantified using a DNA bromodeoxyuride (BrdU) incorporation 
assay (Millipore, Watford, UK), or EdU according to the manufacturer’s instructions. Briefly, 
cells were plated and quiesced in 0.2% FCS media for 48 h prior to stimulation. Cells were 
stimulated with either 10 ng/mL IL1α, 20 ng/mL PDGF or a combination of both for the stated 
times. For BrdU experiments, 6 h after stimulation cells were incubated with BrdU and for 
EdU experiments EdU was added at the point of stimulation for the remaining time to allow 
cell proliferation. BrdU: after removing the culture medium, the cells were fixed followed by 
incubation with anti-BrdU antibody which binds the incorporated DNA. After adding the 
substrate solution, the immune complexes were detected using a plate reader set at dual 
wavelength of 450/550 nm, Victor (Perkin Elmer, Waltham, USA). EdU: following stimulation, 
cellular RNA was extracted as described earlier or fixed in 70% ethanol for EdU FACs 
analysis. EdU incorporation was quantified using Click-it EdU Proliferation assay with an 
Alexa Fluor 594 antibody according to the manufacturer's protocol (Life Technologies). 
 MEKK1 and P38 inhibitor studies 
For inhibitor studies, HSVSMC were plated and quiesced for 48 h. One hour prior to 
stimulation, cells were incubated with either 10, 15 or 20 µM AZD6244 (MEKK1 inhibitor, 
Selleckchem, Suffolk, UK) or 5, 10 or 20 µM P38 (SB 203580). Cells were then maintained 
in either 0.2% media or stimulated with a combination of IL1α and PDGF for 24 h before 
RNA isolation. 
 
 
5’ and 3’ RACE 
5’ 3’ Rapid amplification of cDNA ends 1 was performed to determine the full length transcript 
of SMILR using the SMARTer RACE 5’/3’ Kit (Clontech, Saint-Germain-en-Laye, France) 
according to manufacturer’s instructions. Nested PCR was used to ensure only specific 5’ 
and 3’ products were detected (PCR Primer sequence – Suppl. Table 1). Following cloning 
into supplied cloning vector, products were sequenced. 
 
Fluorescent in situ hybridisation 
Custom RNA-FISH tiled probe sets were generated to all exons of SMILR. RNA FISH 
utilises “branch tree” technology. Briefly, a target specific probe set, containing 40 oligo 
probes, hybridises to the target mRNA as 20 oligo pairs. Each oligo pair forms a required 
platform for assembly of the signal amplification structure (tree) through a series of 
sequential hybridisation steps. Each fully assembled structure, covers a space of 40-50 nt of 
the target RNA, and has the capacity for 400-fold signal amplification. Therefore, a typical 
RNA probe set (containing 20 oligo pairs) has the capacity to generate 8,000-fold signal 
amplification. Due to this technology the company confirms single-molecule RNA sensitivity, 
thus each fluorescent signal corresponds to an individual lncRNA molecule.  
Control SNORD3 and UBC were used as housekeepers to determine spatial location of 
SMILR (Panomics, Affymetrix, California, US). RNA-FISH was performed according to 
manufacturer’s instructions (ViewRNATM cell FISH) with minor modifications for both cell and 
tissue experiments. For cellular analysis, HSVSMC ± IL1α/PDGF were grown on 16-mm 
coverslips to 80% confluency, washed in PBS and fixed in 4% paraformaldehyde 
supplemented with 1% glacial acetic acid. Following detergent QS permeabilisation and 
1:6000 protease digest, coverslips were incubated with a combination of UBC and SMILR 
probe sets or UBC. Probe set buffer was used as a negative control and SNORD3 as 
confirmation of nuclear permeabilisation. Following probe hybridisation, cover slips were 
incubated with branched tree technology pre amplifier for 1 h and amplifier for 30 min. Cover 
slips were finally incubated with fluorescent probes, mounted onto glass slides using Prolong 
gold anti-fade with DAPI mounting medium (Life Technologies).  
 
Image acquisition 
Images acquired on a Zeiss 510 confocal system. At least 5 images were taken per 
condition. Parameters for acquisition and post analysis were identical for all conditions. 
Images were Z stacked to confirm nuclear localisation.  
 
Dicer substrate siRNA (dsiRNA) mediated transfection 
Double stranded dicer substrate siRNA targeting SMILR and Si-control were synthesised 
(Integrated DNA Technologies, Leuven, Belgium). The Si-control does not target any 
sequence in the human, mouse, or rat transcriptomes. Transient transfection was performed 
with Lipofectamine 2000 (Life Technologies). Cells were transfected with either 25 nM Si-
SMILR or Si-Control. Six hours post transfection, cells were quiesced for 48 h and stimulated 
for a further 48 h with 0.2% media containing IL1α/PDGF.  
Lentiviral mediated infection 
Lentiviral vectors were produced by triple transient transfection of HEK293T cells with a 
packaging plasmid (pCMV∆8.74), a plasmid encoding the envelope of vesicular stomatitis 
virus (VSVg) (pMDG) (Plasmid Factory, Bielefeld, Germany) and pLNT/SFFV-MCS plasmid 
employing polyethylenimine (PEI; Sigma-Aldrich, St Louis, USA) as previously described. 
Lentiviral titres were ascertained by TaqMan quantitative real-time PCR (qRT-PCR) using 
the following primer/probe sequences: forward, 5’-TGTGTGCCCGTCTGTTGTGT-3'; 
reverse, 5'- GAGTCCTGCGTCGAGAGAGC-3'; probe, 5'-(FAM)-
CAGTGGCGCCCGAACAGGGA- (TAMRA)-3. SMILR was cloned into the pLNT/SFFV-MCS 
(kind gift from Adrian J. Thrasher, London, UK) plasmid using Platinum taq polymerase, 
according to manufacturer’s instructions, to create pLNT/SFFV-MCS-SMILR. A confluent 
monolayer of smooth muscle cells were plated and infected with a multiplicity of infection of 
either 25 or 50, neither of which induced any form of toxicity in our cells. Following 24 h 
infection, media was changed to 0.2% for a further 48 h. Cells were then stimulated and EdU 
incorporation or SMILR expression investigated as above. 
 
Detection of LncRNA in exosomes secreted from HSVSMC 
SMILR expression in conditioned media utilising both ultracentrifugation and exosome 
isolation kits. RNA extraction of exosome free HSVSMC media was performed using a 
standard volume (15 mL). The conditioned media was centrifuged at 2000 g at 4°C for 10 
min and then at 12000 g for 45 min to remove all cell debris. The supernatant was filtered 
(0.22 µm) followed by ultracentrifugation at 110 000 g, 4°C for 90 min (Optima L-80 XP 
ultracentrifuge Beckman coulter) to obtain microvesicles (MV) and exosomes and exosome 
free media compartments. Additional experiments were performed utilising the Total 
exosome isolation kit (Life technologies) following the manufacturer’s instructions. The 
presence of microvesicles and exosomes was verified using the Nanosight technology  
For exosomes and microvesicles, 700 µL of Qiazol (Qiagen) was added and 3 µL of 
c.elegans total RNA at 25 ng/µL and the RNA was extracted using miRNEasy mini kit 
(Qiagen) as previously described. For the exosome free media compartment, RNA was 
extracted from 2 mL and following the same protocol as describe in the manuscript. SMILR 
relative expression was determined in theses 2 compartments by qRT-PCR.  
 
In Vivo Studies Atherosclerosis Studies: Patients, Imaging and Sampling 
Carotid cohort 
Patients with symptomatic carotid artery stenosis (≥50% by NASCET criteria 2) scheduled to 
undergo carotid endarterectomy were recruited from neurovascular clinics at the Royal 
Infirmary of Edinburgh between January 2013 and April 2014. Exclusion criteria included a 
modified Rankin score of 3, insulin-dependent diabetes mellitus, women of child-bearing age 
not receiving contraception, severe chronic kidney disease (eGFR <30 mL/min/1.73 m2), 
known iodine-based contrast media allergy, prior ipsilateral carotid intervention, prior neck 
irradiation, and inability to provide informed consent. Patients underwent a standard baseline 
clinical assessment including blood sampling (for standard clinical haematological and 
biochemical indices, including C reactive protein, and plasma RNA analysis) before 
undergoing separate [18F]-fluoride and [18F]-fluorodeoxyglucose ([18F]-FDG) positron 
emission tomography 3 combined with computed tomography (CT) scans with the use of a 
hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany). Both of 
these tracers have been used by our group and others for plaque imaging and highlight 
high-risk actively calcifying 4 and inflamed or hypoxic atherosclerotic plaques. 
For [18F]-fluoride imaging, a target dose of 250 MBq was administered intravenously. 
Scanning took place after a 60-min delay. Following an attenuation-correction CT scan (non-
enhanced, low dose 120 kV, 50 mAs) PET imaging was performed in static mode covering 2 
bed positions (15 min each) with the superior bed centered over the carotid bifurcation. 
Following PET acquisition, a CT carotid angiogram was performed without moving the 
patient (Care Dose 4D, 120 kV, 145 mA, rotation time 0.5 s, pitch 0.8). 
[18F]-FDG PET/CT was performed on a separate day. A target dose of 125 MBq was 
administered intravenously and scanning commenced after a 90-min delay. PET/CT 
acquisition was identical to [18F]-Fluoride save for a longer bed time of 20-min and a pre-
scan fast of 6 h. Static images were reconstructed using the Siemens Ultra-HD algorithm 
(time of flight + True X) with corrections applied for attenuation, dead time, scatter, and 
random coincidences.  
PET tracer uptake was quantified using an OsiriX workstation (OsiriX version 3.5.1 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). PET/CT image data were reviewed for 
evidence of tracer uptake, image quality and registration. The CT angiogram was examined 
to establish plaque presence, location and characteristics. Regions of interest 5 were then 
drawn on three adjacent 3-mm PET slices to incorporate the internal carotid artery plaque. 
Three ROI were then drawn around adjacent healthy portions of carotid artery and the lumen 
of the SVC to derive control values for “normal” arterial uptake and the blood pool 
respectively. Arterial standardized uptake values (SUV) were recorded and also indexed to 
blood pool activity thus giving a target-to-background-ratio (TBR). 
At the time of surgery, plaques were collected immediately following excision and 
photographed. Two-millimeter diameter core biopsy specimens for RNA analysis were taken 
from regions of focally high uptake on PET and from normal tissue at the periphery of the 
endarterectomy specimen. These, along with the main specimen, were immediately frozen 
and placed in an -80°C fridge for subsequent batch analysis. Patient characteristic found in 
Suppl. Table. 5.  
 
 
Assessment of lncRNA in human plasma 
A standard volume of each plasma sample (300 µL) was used to extract RNA. Five volumes 
of QIAzol lysis reagent (Qiagen) was added per extraction and supplemented with spike-in 
RNA controls: 3.5 µL of miRNeasy Serum/Plasma Spike-In Control at 1.6 x 108 copies/µL 
(C. elegans miR-39 miRNA mimic; Qiagen) and 3 µL of c.elegans total RNA at 25 ng/µL. 
Following 5-min incubation at RT, chloroform was added at equal volumes to the starting 
sample. Following centrifugation (15 min; 8000 g; 4°C) the clear upper aqueous phase was 
used to isolate RNA as above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1: Sybr green primer sequences. Exon spanning lncRNA primers were 
designed to each lncRNA to ensure no genomic DNA was assessed during qRT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2: IL1α stimulation Ingenuity Pathway analysis. Top 10 disease and  
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with IL1α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 3: PDGF stimulation Ingenuity Pathway analysis. Top 10 disease and 
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with PDGF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4: IL1α + PDGF stimulation Ingenuity Pathway analysis. Top 10 disease and 
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with IL1α and PDGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: Spike-in method of C.elegans total RNA in whole HSVSMC media. (A): 
Dose response effect of C.elegans ama-1 expression. Expression determined by qRT-PCR and 
results displayed as 1/Ct. Number at the top of each histogram corresponds to Ct values. (B): 
Specificity of products analysis by melting curve. (C): Specificity of products analysed using agarose 
gel. The cDNA amplicon size has been resolved by migration on a 2% agarose gel using 100 bp 
ladder. (D): Correlation between quantity spike-in and ama-1 expression. C.elegans ama-1 
expression follow a logarithmic function: y=-1.231ln(x)+30.406 with a coefficient of correlation 
r2=0.9668. (E): Reproducibility of the technique. Following RNA extraction after 75 ng of spike-in total 
C.elegans RNA, ama-1 expression was determined by qRT-PCR and the results have been displayed 
as Ct. 
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Supplemental Figure 2: Assessment of RNA-seq data. (A): Biotype distribution of all transcripts 
identified by RNA-seq analysis generated from HSVSM cells treated with IL1α and PDGF, cutoff at 
FPKM>0.1 (B): IPA analysis of top protein coding genes following IL1α and PDGF treatment. 
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Supplemental Figure 3: Identification of differentially expressed LncRNAs in HSVSMC treated 
with IL1α and PDGF. Transcripts differentially expressed between 0.2% and stated treatment 
(p<0.01), pie chart indicates the relative percentage, and tables present numbers, of each biotype 
differentially expressed. LncRNAs differentially expressed between 0.2% vs IL1α/PDGF can be 
subdivided based on lncRNA biotype. Groups include intervening lncRNA (lincRNA), antisense, 
overlapping and processed transcripts. 
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Supplemental Figure 4: Heat map of most significantly dysregulated intervening lncRNAs 
across all treatment groups. Heat map shows most significant changes in intervening lncRNA 0.2% 
vs IL1+PDGF treatment. LincRNA cut off using FDR<0.01, FPKM>1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5: Dissociation curves and gel products of PCR reactions indicating 
single PCR products.  (A-H) Dissociation curves and gels for each lncRNA primer set. Primers were 
tested under 0.2% and IL1+PDGFconditions. Each gel also contains lanes containing –ve RT and 
H2O samples. 
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Supplemental Figure 6: LncRNA tissue and cell specificity analysis. (A): Expression of LncRNAs 
in a healthy tissue panel. Expression determined by qRT-PCR and results displayed as 1/∆CT. (B): 
Expression of lncRNAs in unstimulated HSVSMC, HSVEC or HCAVSMC.  
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Supplemental Figure 7: Validation of additional SMILR primers. (A-C): Assessment of SMILR via 
qRT-PCR expression via 3 independent primer sets. The number on top of graphs represent Ct 
values obtained under 0.2% and dual stimulated conditions.  
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Supplemental Figure 8: Temporal regulation of lncRNA 2 assessed by qRT-PCR. HSVSMC were 
stimulated with IL1α, PDGF of a combination for the stated time points. RNA was extracted and 
expression determined by qRT-PCR. 
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RP1194A24.1LncRNA2  
GCTGCAAACATTGGGATCAGCCGTGACTATCCCATAACATAATATTTCTGATTTCATTCTTTT
CCTTTCTCCTACCAATTTAATCTGCAATCACTTCAAGAGAAGTCTGTTTAAAGGATATTCACA
TTCTG (intron1-11,398) 
TTCACAGAGTTTGAGAGAAACTGTATTCAAGTTGCTGAAACCAAGAAGCTACACTCACGAGT
CTCACCTAAACTCGAATCTGATTTAGATGACATCATCCTGGACTTTGAGTTGATGAAACCTTG
GAGGTCTTGGGAGTAAAGCAAGTGTGATTTGCATATGATGGATATGAATTGTAATGGCCAGA
GCATGGCTGTG (intron 2- 2,269) 
AGATGAAAACTCCCATTTTAGGGAACCAAGACTGAATTCCATAATTTACATGGATGTTTGGAA
GGTGTCTGCAACTTAATCTGTGTTCGTTTCTGAGATGTTGGGCAACTCCTTCTTGGAAGATG
TGGTAATGGTCTCTTCGAAAAGAAAATAATCATCTGAGTTTTGGCCAAAATAGTTGATCGGAT
TACCTATGAAAATGACTCTCACCCAACTACAAGAATGTTATGATGTAGAAACTCTAAATATAT
GAGTAATTAACTATACAACACTCCATCCCCATGTGAAAATCTTTAATCTTTTAAGATACTGAAA
TTTTGTGTATGTCTCATAATTTTCTGTATATGGTCAATGAGTTTTGCCTTAGCCATAAGTGGT
CTGTCTGAAATCTTCTCTATTATTTGTGCATTTTCTTCCTGATGTACCAAGCCTAGTCTGTTTG
TTTTTTCCTAAGAGAAAAGCAGATGATTCAACTGTGTATTTCTCAGTGTTGATATTGTGGTTT
GAGGTATTTCATAATCTTGAGTAAAATCTTGTCATAAAAAAAAAAAAAAAAAAAAA 
Supplemental Figure 9: Visual representation of full SMILR transcript. (A):Grey boxes indicate 
the predicted SMILR sequence obtained from UCSC genome browser (RP11-94A24.1) . Black boxes 
represent additional 316 basepair sequence obtained via 3’ RACE of SMILR transcript. ***P<0.001, ** 
P<0.01 and * P<0.05 vs 0.2% in each time point (1 way ANOVA). (B): Full length sequence of 
lncRNA 2.   
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SMILR Raw RNA-seq Reads – Control (0.2%) and stimulated (IL1 + PDGF)  
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Supplemental Figure 10: Raw sequencing profiles generated utilising tophat files, constructed 
on integrative genome viewer (IGV). (A): Raw sequencing reads of SMILR under both basal and 
dual stimulated (IL1 + PDGF) conditions n=4. (B): Raw sequencing reads of HAS2 indicating a similar 
expression pattern following stimulation. (C): Raw sequencing reads of SMILR under stimulated 
conditions – expanded (D): Northern analysis of miR146a and SMILR RNA. U6 shown as loading 
control. 
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Supplemental Figure 11: Exosome isolation from HSVSMC conditioned media. (A): Size evaluation using 
the Nanosight of exosomes and MV isolated using the Total exosome isolation kit from 0.2% conditioned media. 
Sizes obtained between 70 and 600 nm. (B): Quantification of miR-143 in exosomes/MV isolated using the Total 
exosome isolation kit from 0.2% conditioned media. (C): SMILR expression analysed by qRT-PCR in 
exosomes/MV and exosomes/MV free media compartment from IL-1α + PDGF conditioned media. (D): Agarose 
gel of qRT-PCR products obtained in C; 1: exosomes/MV compartment, 2: exosomes/MV free media. (E): 
melting curves and gel electrophoresis of SMILR primer set in conditioned media. (F): SMILR expression from 
conditioned media following control lentivirus or SMILR lentivirus infection of cells. (G): Subsequent proliferation 
of quiesced cells following 48h incubation with lentivirus conditioned media.  
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Supplemental Figure 12: Proliferation of HSVSMC 0.2% vs IL1 + PDGF treatment. P<0.05 
students t test.  
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Supplemental Figure 13: (A): Confirmation of siRNA mediated down regulation of SMILR using second 
siRNA targeting a separate sequence of SMILR. (B): Confirmation of knockdown of SMILR using second 
siRNA. Analysed by students t-test ***P<0.001 vs SiControl. (C-D):qRT-PCR analysis of interferon gamma 
associated mRNA OAS1 and IRF7. (E-F): qRT-PCR validation of HAS1 and HAS3 regulation by IL1α and 
PDGF. One way ANOVA *P<0.05. (G-I): Validation of siSMILR using second siRNA targeting different 
section of the lncRNA. 
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Supplemental Figure 14: Effect of HAS2 and HAS2-AS1 knockdown on SMILR expression.  (A): 
Knocdown of HAS2 or HAS2-AS1 both reduced HAS2 expression. (B): Knockdown of neither HAS2 
nor HAS2-AS1 affected SMILR expression levels. (C): Knockdown of HAS2 –AS but not HAS2 
significantly reduced HAS2-AS1levels. (D-F): Overexpression of SMILR did not affect HAS1-HAS3 
nor HAS1-AS1 expression levels.  
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Supplemental Table 5- Baseline Patient Characteristics – Carotid Cohorts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 6- Baseline Patient Characteristics – CRP matched plasma samples. Values 
are represented in mean ± SEM with p values calculated by one-way ANOVA or by Fisher's exact test 
for categorical variables. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 15: Primer validation and quality control in plasma samples.  (A): Melting 
curve for SMILR in plasma. (B): Agarose gel of qPCR product. (C): Water melting curve. 
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  The Pearson correlation: 
 
 
    So r=0.5719, r2=0.327, p<0.001 
  
 
                                               
   If we take out the two outliers (the two highest dCts): 
 
 
 
 
 
         r=0.389, r2=0.151, p=0.014 
 
 
 
 
 
 
Supplemental Figure 16: Statistical analysis of SMILR vs. CRP correlation. (A): Pearson 
correlation of SMILR vs. CRP utilising all data points. R=0.5719, r2=0.327 and P<0.001. (B): Pearson 
correlation of SMILR vs. CRP omitting the 2 highest outlying points. R=0.389, r2=0.151, p=0.014.  
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